Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Semren, M. Korfei, I. Fernandez, A. Günther, O. Eickelberg, S. Meiners (München, Giessen, Germany). Proteasome function in pulmonary fibrosis. Eur Respir J 2014; 44: Suppl. 58, 1421

Member's Comments

Peter Josefsson (Trelleborg, Sweden) - 07.09.2014 22:14
is it possible to have a copy of the poster?peter.josefsson@nigaard.com

Related content which might interest you: The role of Frizzled8 in idiopathic pulmonary fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Altered protein homeostasis in pulmonary fibrosis indicates a role for proteasomal activator 200 Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Regulation of WISP1 by profibrotic cytokines in pulmonary fibrosis Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014 Resveratrol regulates ECM remodeling in lung fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Loss of CARM1 prolongs bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Neutrophil elastase degraded elastin is elevated in serum of idiopathic pulmonary fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Severe lung inflammation is a feature of IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Lipoxin (LXA4) as a novel therapy for idiopathic pulmonary fibrosis Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Functional and molecular disparities between mesenchymal stem cells from various pulmonary disorders Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014 Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Impact of Wnt ligand secretion on cellular phenotypes in pulmonary fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Matriptase triggers pleiotropic functional responses in normal human lung fibroblasts (NHLF): Potential relevance in pathophysiology Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 LATE-BREAKING ABSTRACT: Age-related PINK1 deficiency promotes mitochondria dysfuntion, epithelial injury and fibrosis in the lung Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 MiR-214-3p, a new fibromiR involved in the pathogenesis of idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Pulmonary fibroblasts are affected by notch ligands in vitro Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015